Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March.
It comes after the country's drugs cost-effectiveness watchdog gave its blessing on Monday (December 23).
Mounjaro launched in Britain in February but has been available only for those paying privately.
The National Institute for Health and Care Excellence, is recommending Mounjaro, alongside diet and exercise changes.
That will be for people with at least one weight-related condition, such as heart disease or type-2 diabetes, and a body mass index of more than 35.
The eligibility guidelines are the same as those issued for Wegovy, the obesity medication made by rival drugmaker Novo Nordisk.
Mounjaro is a weekly injection.
And has led to an average weight loss of nearly 23% in clinical trials.
https://finance.yahoo.com/video/lilly-obesity-drug-mounjaro-offered-164244848.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.